AUTHORS
Marc-Andrea Baertsch, MD, Katharina Kriegsmann, MD2, Varun R Ginde3, Michael Benn4, Hans-Juergen Salwender, MD5, Axel Benner6, Marina Hajiyianni, MD7, Lilli Sophie Sester, MD8, Lukas John, MD9, Carsten Mueller-Tidow, MD10, Elias K. Mai, MD11, Marc-Steffen Steffen Raab, MD12, Michael Hundemer, MD13, Hartmut Goldschmidt, MD14, Sandra Sauer, MD15
AFFILIATIONS
1 German Cancer Research Center (DKFZ), Heidelberg, Germany, Heidelberg University Hospital, Heidelberg, Germany
2 Laborarztpraxis Rhein-Main MVZ GbR, Frankfurt, Germany
3 German Cancer Research Center (DKFZ), Heidelberg, Germany
4 Heidelberg University Hospital, Heidelberg, Germany
5 Asklepios Klinik Altona and Asklepios Klinik St. Georg, Hamburg, Germany
6 German Cancer Research Center (DKFZ), Heidelberg, Germany
7 Heidelberg University Hospital, Heidelberg, Germany
8 Heidelberg University Hospital, Heidelberg, Germany
9 Heidelberg University Hospital, Heidelberg, Germany
10 Heidelberg University Hospital, Heidelberg, Germany, Heidelberg University Hospital, Heidelberg, Germany
11 Heidelberg University Hospital, Heidelberg, Germany
12 German Cancer Research Center (DKFZ), Heidelberg, Germany, Heidelberg University Hospital, Heidelberg, Germany, Heidelberg University Hospital, Heidelberg, Germany
13 Heidelberg University Hospital, Heidelberg, Germany, Heidelberg University Hospital, Heppenheim, Germany
14 Heidelberg University Hospital, Heidelberg, Germany, Heidelberg University Hospital, Heidelberg, Germany
15 Heidelberg University Hospital, Heidelberg, Germany
ABSTRACT
Introduction
Measurable residual disease (MRD) status assessed in the bone marrow (BM) is one of the strongest prognostic factors for survival in newly diagnosed multiple myeloma (NDMM). Assessment of MRD in the autologous stem cell product (AP) is non-invasive and AP-MRD negativity is associated with favorable outcome after frontline transplant. However, the impact of state of the art anti-CD38 antibody containing regimens on AP-MRD status remains poorly characterized.
Methods
Patients treated in the GMMG HD7 (isatuximab/lenalidomide/bortezomib/dexamethasone [Isa-RVd] vs. RVd induction; NCT03617731) and GMMG HD6 (elotuzumab-RVd [Elo-RVd] vs. RVd induction; NCT02495922) trials at two major trial sites with available cryopreserved material were assessed for AP-MRD at a sensitivity of 10-5 by next generation flow (NGF) using the EuroFlow protocol. In the GMMG HD7 trial BM-MRD (NGF/EuroFlow; sensitivity 10-5) was assessed after induction treatment and after transplant, whereas in the GMMG HD6 trial BM-MRD was assessed after transplant and only patients achieving CR after induction were assessed for BM-MRD at the post induction timepoint. Associations between AP-MRD and BM-MRD were compared by chi-squared test and a multivariate logistic regression model adjusting for key covariates. Progression-free survival (PFS) was estimated according to Kaplan-Meier and compared by two-sided log-rank test.
Results
A total of n=162 patients were assessed for AP-MRD (Isa-VRd: n=51, Elo-VRd: n=29, VRd: n=82). Overall, n=122 patients (75.3%) achieved AP-MRD negativity. Patients achieving AP-MRD negativity had a lower baseline rate of anemia (n=33/122 [27%] vs. 22/40 [55%], p=0.002), hypercalcemia (n=4/122 [3.3%] vs. n=5/40 [12.5%], p=0.04) and involved/uninvolved free light chain ratio >100 (n=52/122 [42.6%] vs. 28/340 [70%], p=0.003), as well as a higher rate of SLiM without CRAB criteria (n=23/122 [18.8%] vs. 2/40 [5%], p=0.02).
Patients receiving Isa-RVd but not Elo-RVd achieved a higher rate of AP-MRD negativity compared to RVd (n=47/51 [92.2%], n=22/29 [75.9%] n=53/82 [64.6%], respectively; Isa-RVd vs. RVd: p=0.0008; Elo-RVd vs. RVd: p=0.38). BM-MRD negativity after induction was strongly associated with AP-MRD negativity: n=40/42 patients [95.2%] with BM-MRD negativity also achieved AP-MRD negativity. In BM-MRD positive patients the rate of AP-MRD negativity was 56.9% (n=33/58 patients). In BM- and AP-MRD positive patients, tumor load in BM after induction was at median 22.7-fold higher compared to AP (range 0.1- to 190-fold; p<0.0001).
AP-MRD status predicted BM-MRD status post-transplant: n=74/101 AP-MRD negative patients [73.3%] but only n=10/33 AP-MRD positive patients [30.3%] achieved BM-MRD negativity post-transplant (p=0.00002). The predictive value of AP-MRD negativity for BM-MRD negativity post-transplant was retained in a multivariate model (OR 3.3, 95%-CI 1.3-8.8, p=0.015) including induction regimen (Isa-RVd vs. Elo-RVd/RVd), IMWG response status (nCR/CR vs. <nCR) post-induction, and R-ISS as covariates. AP-MRD negativity was associated with improved PFS in the overall cohort (median NR [95% CI: NR vs. NR] vs. 4.2 [95% CI: 2.9-NR] years; p=0.003) as well as in the subgroup of patients achieving BM-MRD negativity post-transplant (median NR [95% CI: NR vs. NR] vs. 4.2 [95% CI: 3.3-NR] years; p=0.007).
Conclusions
AP-MRD negativity is associated with improved PFS in NDMM patients receiving RVd-based triplet/quadruplet induction regimens. Isatuximab during induction treatment results in an improved AP-MRD negativity rate, similar to what we have previously reported for BM-MRD. AP-MRD status predicts BM-MRD status after transplant. Thus, AP-MRD profiling is a non-invasive alternative to BM-MRD profiling at an early (pre-transplant) timepoint but detectable tumor load is ~20-fold lower in AP compared to BM. Higher sensitivity AP-MRD profiling beyond the 10-5 level should be evaluated in patients receiving state of the art, anti-CD38-containing quadruplet induction regimens.
DISCLOSURES
Marc-Andrea Baertsch, MD: Stemline - Honoraria; Pfizer - Honoraria; GSK - Honoraria; Sanofi - Honoraria; Sanofi - Research Funding; GSK - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Stemline - Consultancy (Includes expert testimony)